Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Linda Chrit"'
Autor:
Gianmatteo Pica, Enrique Báez de la Fuente, Jan Van Droogenbroeck, Sorin Visanica, Brian Leber, Timothy Devos, Hacene Zerazhi, Antonio Almeida, Albert Kandra, Linda Chrit, Jean-Jacques Kiladjian, Dana Ranta, Juliane Morando, Lynda Foltz
Publikováno v:
Leukemia & Lymphoma. 60:3493-3502
Ruxolitinib was recently approved for the treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea based on data from the RESPONSE studies. This phase 3b, Expanded Treatment Protocol study (NCT02292446) of ruxolitinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f605dfd5993e44330daad2fab631c2d6
https://doi.org/10.1080/10428194.2019.1636985
https://doi.org/10.1080/10428194.2019.1636985
Autor:
Mauricio Reyes Cartes, Sorin Visanica, Gianmatteo Pica, Antonio Almeida, Timothy Devos, Jean-Jacques Kiladjian, Hacene Zerazhi, Enrique Báez de la Fuente, Juliane Morando, Lynda Foltz, Zhaoyu Yin, Jan Van Droogenbroeck, Brian Leber, Linda Chrit, Dana Ranta
Publikováno v:
Blood. 132:1774-1774
BACKGROUND Few Tx options are available for pts with inadequately controlled PV. European LeukemiaNet defined resistance/intolerance was seen in ≈25% pts treated with HU (Alvarez-Larran et al, 2012). In the HU-resistant/intolerant PV pts evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19ff0973f26ce97a893fdc669f5a1360
https://doi.org/10.1182/blood-2018-99-111479
https://doi.org/10.1182/blood-2018-99-111479